Once-daily gabapentin enacarbil (Horizant) is effective in patients with the most severe cases of restless legs syndrome, reports HCP Live, citing a presentation at the American Academy of Neurology Annual Meeting.
The study found statistically significant mean differences in IRLS score for both GEn 600 mg, versus placebo (-4; P = 0.03), and GEn, 1200 mg versus placebo (-5.7;P < 0.001). Compared with placebo, both doses of GEn significantly improved IRLS total score from baseline at each time point during the 12-week trial. “We’re excited to say that this study demonstrated that even those individuals who suffer from severe RLS can benefit from gabapentin enacarbil,” said Lee.
